Hainanhaiyao's Novel Anti-Hepatic Fibrosis Drug Completes Phase II Trial

Stock News

06/24

Hainanhaiyao Co.,Ltd. (SHE: 000566) has announced the completion of a Phase II clinical trial for its innovative anti-hepatic fibrosis drug, Flufenidone Capsules, with the Phase III study now progressing as scheduled.

Concurrently, the company's novel anti-epileptic drug, Paienjiabin Tablets, has concluded its Phase IIa trial, and the Phase IIb clinical trial is advancing according to plan.

The company highlights that new drug development is characterized by long cycles, substantial investment, and high risks. The clinical trial process and outcomes involve numerous uncertainties, and there is no guarantee of subsequent regulatory approval for market launch. These developments are not expected to have a significant impact on the company's financial performance in the short term.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1106638512"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106638512\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106638512?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106638512","market":"hk","top_or_hot":-1,"title":"Hainanhaiyao's Novel Anti-Hepatic Fibrosis Drug Completes Phase II Trial","media":"Stock News","content":"<p><b>Hainanhaiyao Co.,Ltd.</b> (<b>SHE: 000566</b>) has announced the completion of a Phase II clinical trial for its innovative anti-hepatic fibrosis drug, Flufenidone Capsules, with the Phase III study now progressing as scheduled.<br><br>Concurrently, the company's novel anti-epileptic drug, Paienjiabin Tablets, has concluded its Phase IIa trial, and the Phase IIb clinical trial is advancing according to plan.<br><br>The company highlights that new drug development is characterized by long cycles, substantial investment, and high risks. The clinical trial process and outcomes involve numerous uncertainties, and there is no guarantee of subsequent regulatory approval for market launch. These developments are not expected to have a significant impact on the company's financial performance in the short term.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hainanhaiyao's Novel Anti-Hepatic Fibrosis Drug Completes Phase II Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHainanhaiyao's Novel Anti-Hepatic Fibrosis Drug Completes Phase II Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-24 21:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Hainanhaiyao Co.,Ltd.</b> (<b>SHE: 000566</b>) has announced the completion of a Phase II clinical trial for its innovative anti-hepatic fibrosis drug, Flufenidone Capsules, with the Phase III study now progressing as scheduled.<br><br>Concurrently, the company's novel anti-epileptic drug, Paienjiabin Tablets, has concluded its Phase IIa trial, and the Phase IIb clinical trial is advancing according to plan.<br><br>The company highlights that new drug development is characterized by long cycles, substantial investment, and high risks. The clinical trial process and outcomes involve numerous uncertainties, and there is no guarantee of subsequent regulatory approval for market launch. These developments are not expected to have a significant impact on the company's financial performance in the short term.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"000566","symbol_name":"海南海药","start_time":0,"source_url":"","article_id":"1106638512","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106638512","pubTimestamp":1782306681,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hainanhaiyao Co.,Ltd. (SHE: 000566) has announced the completion of a Phase II clinical trial for its innovative anti-hepatic fibrosis drug, Flufenidone Capsules, with the Phase III study now...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","000566":"海南海药","BK0146":"智慧医疗","BK0239":"医药制造","06978":"永泰生物-B","BK1161":"生物科技","BK0070":"员工持股","BK0188":"融资融券","BK1574":"生物医药B类股","BK0060":"抗癌"},"translate_title":"海南海药抗肝纤维化新药完成II期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06978":1,"000566":1},"content_text":"Hainanhaiyao Co.,Ltd. (SHE: 000566) has announced the completion of a Phase II clinical trial for its innovative anti-hepatic fibrosis drug, Flufenidone Capsules, with the Phase III study now progressing as scheduled.Concurrently, the company's novel anti-epileptic drug, Paienjiabin Tablets, has concluded its Phase IIa trial, and the Phase IIb clinical trial is advancing according to plan.The company highlights that new drug development is characterized by long cycles, substantial investment, and high risks. The clinical trial process and outcomes involve numerous uncertainties, and there is no guarantee of subsequent regulatory approval for market launch. These developments are not expected to have a significant impact on the company's financial performance in the short term.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}